• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intuitive Surgical Q4 prelims beat estimates

Intuitive Surgical Q4 prelims beat estimates

January 11, 2017 By Sarah Faulkner

Intuitive Surgical Q4 prelims beat estimatesIntuitive Surgical (NSDQ:ISRG) shares gained after it posted preliminary financial results for the 4th quarter, beating analysts’ expectations on Wall Street.

The Sunnyvale, Calif.-based company said it expects a total revenue of $757 million for Q4, up from $677 million in the same period last year. Analysts were looking for sales of $739.7 million in Q4. Intuitive also said it anticipates a full-year revenue of $2.7 billion, compared to the Street’s $2.4 billion consensus.

“We are pleased by our 4th quarter results and encouraged by our future opportunities,” president & CEO Gary Guthart said in prepared remarks. “In 2017, we look forward to advancing several key product development innovations targeted towards further improving patient outcomes and expanding the number of patients that can derive the benefits of robotically assisted minimally invasive therapies around the world. We anticipate accelerating up to $80 million of research, development, and clinical investment into 2017.”

ISRG shares were trading at $674.89 apiece in afternoon trading, up +1.9%.

In mid-December, the company said its board of directors increased the authorized amount available under its share repurchase program to $3 billion. The timing and total amount of stock repurchases will vary depending on market conditions, Intuitive said, and may be made in open market purchases, private transactions and otherwise.

In November, Intuitive and Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon agreed to bury the hatchet regarding a former Ethicon representative’s non-compete agreement. Intuitive sued Ethicon in a California federal court in August 2016 and claimed that Ethicon was using “intricate legal gymnastics” to go around the state’s restrictions on non-competes.

Filed Under: MassDevice Earnings Roundup, Surgical Robotics, Wall Street Beat Tagged With: Intuitive Surgical

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy